Eltanexor Plus Inqovi

A Phase I/II Trial of Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1/2
Enrollment
80 patients (estimated)
Sponsors
National Cancer Institute (NCI)
Tags
Chemotherapy, Cytidine Deaminase Inhibitor (CDAi), Nucleoside Metabolic Inhibitor, Selective Inhibiton of Nuclear Export (SINE)
Trial Type
Treatment
Last Update
1 month ago
SparkCures ID
1733
NCT Identifier
NCT05918055

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.